RVPH PE Ratio & Valuation,Is RVPH Overvalued

RVPH Relative Valuation

RVPH's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, RVPH is overvalued; if below, it's undervalued.

Historical Valuation

Reviva Pharmaceuticals Holdings Inc (RVPH) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -3.39. The fair price of Reviva Pharmaceuticals Holdings Inc (RVPH) is between -- to -- according to relative valuation methord.

Relative Value

Fair Zone

-----

Current Price：0.65

Fair

-1.73

0.00

EV/EBITDA

Reviva Pharmaceuticals Holdings Inc. (RVPH) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.

-2.08

EV/EBIT

Reviva Pharmaceuticals Holdings Inc. (RVPH) has a current EV/EBIT of -2.08. The 5-year average EV/EBIT is -2.17. The thresholds are as follows: Strongly Undervalued below -7.24, Undervalued between -7.24 and -4.71, Fairly Valued between 0.37 and -4.71, Overvalued between 0.37 and 2.90, and Strongly Overvalued above 2.90. The current Forward EV/EBIT of -2.08 falls within the Historic Trend Line -Fairly Valued range.

0.00

Reviva Pharmaceuticals Holdings Inc. (RVPH) has a current PS of 0.00. The 5-year average PS is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward PS of 0.00 falls within the Strongly Undervalued range.

-2.45

P/OCF

Reviva Pharmaceuticals Holdings Inc. (RVPH) has a current P/OCF of -2.45. The 5-year average P/OCF is -2.18. The thresholds are as follows: Strongly Undervalued below -5.98, Undervalued between -5.98 and -4.08, Fairly Valued between -0.28 and -4.08, Overvalued between -0.28 and 1.62, and Strongly Overvalued above 1.62. The current Forward P/OCF of -2.45 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

Reviva Pharmaceuticals Holdings Inc. (RVPH) has a current P/FCF of 0.00. The 5-year average P/FCF is -1.36. The thresholds are as follows: Strongly Undervalued below -4.77, Undervalued between -4.77 and -3.07, Fairly Valued between 0.34 and -3.07, Overvalued between 0.34 and 2.04, and Strongly Overvalued above 2.04. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

Reviva Pharmaceuticals Holdings Inc (RVPH) has a current Price-to-Book (P/B) ratio of 14.18. Compared to its 3-year average P/B ratio of 0.58 , the current P/B ratio is approximately 2357.29% higher. Relative to its 5-year average P/B ratio of 2.03, the current P/B ratio is about 597.12% higher. Reviva Pharmaceuticals Holdings Inc (RVPH) has a Forward Free Cash Flow (FCF) yield of approximately -36.44%. Compared to its 3-year average FCF yield of -50.63%, the current FCF yield is approximately -28.02% lower. Relative to its 5-year average FCF yield of -43.01% , the current FCF yield is about -15.27% lower.

13.47

P/B

Median3y

0.58

Median5y

2.03

-36.44

FCF Yield

Median3y

-50.63

Median5y

-43.01

Competitors Valuation Multiple

The average P/S ratio for RVPH's competitors is 0.00, providing a benchmark for relative valuation. Reviva Pharmaceuticals Holdings Inc Corp (RVPH) exhibits a P/S ratio of 0.00, which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of RVPH increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of RVPH in the past 1 year is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is Reviva Pharmaceuticals Holdings Inc (RVPH) currently overvalued or undervalued?

What is Reviva Pharmaceuticals Holdings Inc (RVPH) fair value?

RVPH's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Reviva Pharmaceuticals Holdings Inc (RVPH) is between to according to relative valuation methord.

How does RVPH's valuation metrics compare to the industry average?

What is the current P/B ratio for Reviva Pharmaceuticals Holdings Inc (RVPH) as of Dec 16 2025?

As of Dec 16 2025, Reviva Pharmaceuticals Holdings Inc (RVPH) has a P/B ratio of 14.18. This indicates that the market values RVPH at 14.18 times its book value.

What is the current FCF Yield for Reviva Pharmaceuticals Holdings Inc (RVPH) as of Dec 16 2025?

As of Dec 16 2025, Reviva Pharmaceuticals Holdings Inc (RVPH) has a FCF Yield of -36.44%. This means that for every dollar of Reviva Pharmaceuticals Holdings Inc’s market capitalization, the company generates -36.44 cents in free cash flow.

What is the current Forward P/E ratio for Reviva Pharmaceuticals Holdings Inc (RVPH) as of Dec 16 2025?

As of Dec 16 2025, Reviva Pharmaceuticals Holdings Inc (RVPH) has a Forward P/E ratio of -1.82. This means the market is willing to pay $-1.82 for every dollar of Reviva Pharmaceuticals Holdings Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Reviva Pharmaceuticals Holdings Inc (RVPH) as of Dec 16 2025?

As of Dec 16 2025, Reviva Pharmaceuticals Holdings Inc (RVPH) has a Forward P/S ratio of 0.00. This means the market is valuing RVPH at $0.00 for every dollar of expected revenue over the next 12 months.

RVPH Valuation

RVPH Valuation

RVPH Relative Valuation

Historical Valuation

Competitors Valuation Multiple

Performance Decomposition

People Also Watch

Frequently Asked Questions

Is Reviva Pharmaceuticals Holdings Inc (RVPH) currently overvalued or undervalued?

What is Reviva Pharmaceuticals Holdings Inc (RVPH) fair value?

How does RVPH's valuation metrics compare to the industry average?

What is the current P/B ratio for Reviva Pharmaceuticals Holdings Inc (RVPH) as of Dec 16 2025?

What is the current FCF Yield for Reviva Pharmaceuticals Holdings Inc (RVPH) as of Dec 16 2025?

What is the current Forward P/E ratio for Reviva Pharmaceuticals Holdings Inc (RVPH) as of Dec 16 2025?

What is the current Forward P/S ratio for Reviva Pharmaceuticals Holdings Inc (RVPH) as of Dec 16 2025?